MX2010007923A - Forma cristalina de abacavir que esta esencialmente libre de disolvente. - Google Patents

Forma cristalina de abacavir que esta esencialmente libre de disolvente.

Info

Publication number
MX2010007923A
MX2010007923A MX2010007923A MX2010007923A MX2010007923A MX 2010007923 A MX2010007923 A MX 2010007923A MX 2010007923 A MX2010007923 A MX 2010007923A MX 2010007923 A MX2010007923 A MX 2010007923A MX 2010007923 A MX2010007923 A MX 2010007923A
Authority
MX
Mexico
Prior art keywords
abacavir
crystalline form
solvent
essentially free
acetonitrile
Prior art date
Application number
MX2010007923A
Other languages
English (en)
Inventor
Maimo Ramon Berenguer
Sanmarti Marti Bartra
Jordi Benet-Buchholz
I Carandell Lluis Sola
Original Assignee
Esteve Quimica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39528214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010007923(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Quimica Sa filed Critical Esteve Quimica Sa
Publication of MX2010007923A publication Critical patent/MX2010007923A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Forma cristalina de abacavir que está esencialmente libre de disolvente de fórmula (I), en particular Forma cristalina I, su procedimiento de preparación que comprende las siguientes etapas: a) cristalizar abacavir a partir de una solución de dicho compuesto en un alcohol (C1-C4), diclorometano, acetonitrilo/agua, mezclas de los mismos; b) aislar la forma cristalina de abacavir que aparece en la etapa anterior; y c) eliminar el disolvente de la forma cristalina de abacavir así obtenida. La Forma cristalina I también puede prepararse mediante la dispersión de abacavir en acetonitrilo. La Forma cristalina I que está esencialmente libre de disolvente es útil para la preparación de composiciones farmacéuticas para uso en el tratamiento y/o la profilaxis de infecciones de VIH. (ver fórmula (I)).
MX2010007923A 2008-01-21 2009-01-21 Forma cristalina de abacavir que esta esencialmente libre de disolvente. MX2010007923A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08382004A EP2085397A1 (en) 2008-01-21 2008-01-21 Crystalline form of abacavir
US3844108P 2008-03-21 2008-03-21
PCT/EP2009/050613 WO2009092716A1 (en) 2008-01-21 2009-01-21 Crystalline form of abacavir that is essentially free of solvent

Publications (1)

Publication Number Publication Date
MX2010007923A true MX2010007923A (es) 2010-08-10

Family

ID=39528214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007923A MX2010007923A (es) 2008-01-21 2009-01-21 Forma cristalina de abacavir que esta esencialmente libre de disolvente.

Country Status (15)

Country Link
US (1) US9056864B2 (es)
EP (3) EP2085397A1 (es)
JP (1) JP5468553B2 (es)
KR (1) KR20100103710A (es)
CN (1) CN101925602B (es)
AU (1) AU2009207735A1 (es)
CA (1) CA2711059A1 (es)
ES (2) ES2540461T3 (es)
HR (1) HRP20180865T1 (es)
HU (1) HUE037892T2 (es)
IL (1) IL206731A (es)
MX (1) MX2010007923A (es)
RU (1) RU2010134904A (es)
WO (1) WO2009092716A1 (es)
ZA (1) ZA201004762B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
WO2014079709A1 (en) * 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
CN105315280A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种阿巴卡韦结晶体及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH582370B5 (es) 1973-05-11 1976-11-30 Ebauches Bettlach Sa
US4355032B2 (en) 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5981500A (en) * 1994-01-12 1999-11-09 Pfizer Inc. Antiparasitic agents related to the milbemycins and avermectins
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
EP0918768B1 (en) * 1996-05-31 2002-01-09 C & C Research Laboratories Aromatic amidine derivatives useful as selective thrombin inhibitors
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU2702899A (en) 1997-10-24 1999-05-17 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
US6548663B1 (en) * 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
YU91603A (sh) * 2001-05-22 2006-08-17 Pfizer Products Inc. Kristalni oblici azitromicina
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7211417B2 (en) * 2003-05-02 2007-05-01 Wyeth Holdings Corporation Antibiotic P175-A and semisynthetic derivatives thereof
US7067529B2 (en) * 2003-05-19 2006-06-27 Hoffmann-La Roche Inc. Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
WO2005012256A1 (en) * 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
GB0320738D0 (en) * 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
WO2005049588A1 (en) 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for isolation of valsartan
KR20060127906A (ko) * 2003-12-22 2006-12-13 길리애드 사이언시즈, 인코포레이티드 4'-치환된 카보버와 아바카비어 유도체 및 ｈｉｖ와 ｈｃｖ항바이러스 활성을 갖는 관련 화합물
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
JP2008517066A (ja) * 2004-10-20 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CA2619284C (en) * 2005-08-29 2014-04-29 Sanofi-Aventis U.S. Llc Novel crystalline form of a pyridazino [4,5-b] indole derivative
TW200804409A (en) * 2005-09-13 2008-01-16 Sicor Inc Processes for the synthesis of rocuronium bromide
CN1763040A (zh) 2005-09-15 2006-04-26 上海玛耀化学技术有限公司 阿巴卡韦的制造方法
EP1857458A1 (en) 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
BRPI0717554A2 (pt) * 2006-09-28 2013-10-29 Merck & Co Inc Composição farmacêutica, método para tratar câncer e aliviar os efeitos colaterais do inibidor da hdac, e, método de se obter um complexo de quelato inibidor da hdac de metal
KR101396686B1 (ko) * 2006-09-28 2014-05-16 에스티브 퀴미카 에스.에이. 아바카비어 조제 방법
EP1905772A1 (en) 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP1939196A1 (en) 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists

Also Published As

Publication number Publication date
WO2009092716A1 (en) 2009-07-30
RU2010134904A (ru) 2012-02-27
CA2711059A1 (en) 2009-07-30
EP2242758B1 (en) 2015-03-18
EP2899193B1 (en) 2018-03-14
KR20100103710A (ko) 2010-09-27
CN101925602A (zh) 2010-12-22
IL206731A (en) 2014-06-30
JP5468553B2 (ja) 2014-04-09
ZA201004762B (en) 2011-09-28
IL206731A0 (en) 2010-12-30
ES2540461T3 (es) 2015-07-09
US20100298354A1 (en) 2010-11-25
US9056864B2 (en) 2015-06-16
CN101925602B (zh) 2014-03-12
JP2011510039A (ja) 2011-03-31
EP2085397A1 (en) 2009-08-05
HUE037892T2 (hu) 2018-09-28
EP2242758A1 (en) 2010-10-27
ES2670802T3 (es) 2018-06-01
EP2899193A1 (en) 2015-07-29
HRP20180865T1 (hr) 2018-08-24
AU2009207735A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
WO2008144346A3 (en) Crystal structures of sglt2 inhibitors and processes for their preparation
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
JP2011126894A5 (es)
WO2008075376A8 (en) Polymorphic forms of bortezomib and process for their preparation
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2010029302A3 (en) Compounds for treating viral infections
ECSP099480A (es) Compuestos químicos 637: piridopirimidindionas como inhibidores de la pde4
IN2012DN03176A (es)
WO2012009699A3 (en) Process for preparing antiviral compounds
NZ602109A (en) Plant protection agent
EA201000147A1 (ru) Способ выделения и очистки монтелукаста
AR078916A1 (es) Procedimiento para la purificacion de paliperidona
TW201613931A (en) Form crystal of bisulfate of janus kinase (JAK) inhibitor and preparation method thereof
CL2012000560A1 (es) Procedimiento de preparacion del compuesto intermediario acido 3-oxo-tetrahidrotiofeno-2-carboxilico, utiles en la preparacion de dihidrotienopirimidinas (divisional de la solicitud 3095-08).
WO2013190455A3 (en) Process for the preparation of lurasidone hydrochloride
WO2011004387A3 (en) Process for the preparation of dexlansoprazole polymorphic forms
MX2010007923A (es) Forma cristalina de abacavir que esta esencialmente libre de disolvente.
AR057555A1 (es) Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
WO2014087208A3 (en) A process of preparing alcaftadine
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
WO2015128882A3 (en) Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof

Legal Events

Date Code Title Description
FG Grant or registration